Press Releases
February 16, 2007
Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
PDUFA Date Set for June 18, 2007
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 16, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted a Priority Review for the company's New Drug Application (NDA) for marketing approval of ambrisentan (5 mg and 10 mg) for the once-daily treatment of pulmonary arterial hypertension (PAH).
Priority Review status is assigned to drug products that, if approved, would be a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease. A Priority Review means that the time it takes FDA to review a new drug application is reduced. The FDA goal for reviewing a drug with Priority Review is six months. Gilead submitted its NDA for ambrisentan on December 18, 2006. The FDA has established a target review date, under the Prescription Drug User Fee Act (PDUFA), of June 18, 2007.
About Ambrisentan
Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. Activation of the ETA receptor by endothelin, a small peptide hormone, leads to vasoconstriction and cell proliferation. PAH is associated with elevated endothelin blood levels. Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union.
As an investigational compound, ambrisentan has not yet been determined safe or efficacious in humans.
GlaxoSmithKline holds rights to commercialize ambrisentan in territories outside of the United States.
About Pulmonary Arterial Hypertension
PAH is a debilitating disease characterized by constriction of the blood vessels in the lungs leading to high pulmonary arterial pressures. These high pressures make it difficult for the heart to pump blood through the lungs to be oxygenated. Patients with PAH suffer from shortness of breath as the heart struggles to pump against these high pressures causing such patients to ultimately die of heart failure. PAH can occur with no known underlying cause, or it can occur secondary to diseases such as connective tissue disease, congenital heart defects, cirrhosis of the liver and HIV infection. PAH afflicts approximately 200,000 patients worldwide.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize this product. For example, the FDA may not approve ambrisentan for the treatment of PAH in the United States, and marketing approval, if granted, may have significant limitations on its use. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2005 and Reports on Form 10-Q for the first three quarters of 2006, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)
SOURCE: Gilead Sciences, Inc.